Clinical Trials Browser

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06519526 2026-01-12

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Recruiting

25 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Suspended

24 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT03922724 2025-12-31

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Phase 2 Recruiting

330 enrolled

Lymphoid

Autoimmune Diseases, Immune System Diseases, Lymphoproliferative Disorders, Opportunistic Infections, Lymphoma, T-Cell, Peripheral

NCT06511895 2025-12-24

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Phase 2 Completed

57 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Recruiting

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

Phase 2 Not yet recruiting

31 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Phase 2 Active not recruiting

155 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06160843 2025-09-05

POLAR

Phase 2 Recruiting

24 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

56 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

71 enrolled

Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Phase 2 Not yet recruiting

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06511869 2025-07-04

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Phase 2 Completed

48 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Phase 2 Not yet recruiting

35 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Phase 2 Recruiting

115 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT06941688 2025-04-24

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

17 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

32 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral